
    
      All participants that previously completed the three-dose primary and the booster
      vaccinations in the study E2I34 (NCT 00255021) will be contacted to enroll in this study to
      receive sanofi pasteur's DTacP IPV combined vaccine (Tetraxim™) at 4 to 6 years of age.

      Participants will receive the study vaccine [sanofi pasteur's DTacP-IPV vaccine (TETRAXIM™)]
      at 4 to 6 years of age (at visit 1).
    
  